Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stacey DaCosta Byfield

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Trends in Cell Biology|April 2, 2004
Lateral signaling enhances TGF-beta response complexityStacey DaCosta Byfield, Anita B Roberts
Anticancer Research|January 31, 2021
Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort StudyShaum M Kabadi, Stacey Dacosta Byfield, Lisa LE, et al.
Journal of Oncology Practice|September 24, 2015
ReCAP: Treatment Patterns and Cost of Care Associated With Initial Therapy Among Patients Diagnosed With Operable Early-Stage Human Epidermal Growth Factor Receptor 2-Overexpressed Breast Cancer in the United States: A Real-World Retrospective StudyStacey DaCosta Byfield, Philip O Buck, Cori Blauer-Peterson, et al.
Journal of Comparative Effectiveness Research|January 25, 2021
Economic impact of multigene panel testing for hereditary breast and ovarian cancerStacey Dacosta Byfield, Helen Wei, Mary DuCharme, et al.
Archives of Dermatological Research|April 23, 2013
Age distribution of patients with advanced non-melanoma skin cancer in the United StatesStacey Dacosta Byfield, Diana Chen, Yeun Mi Yim, et al.
Molecular Pharmacology|February 24, 2004
SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7Stacey DaCosta Byfield, Christopher Major, Nicholas J Laping, et al.
Leukemia & Lymphoma|July 12, 2013
Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapyB Douglas Smith, Dalia Mahmoud, Stacey Dacosta-Byfield, et al.
Clinical Sarcoma Research|November 21, 2017
A retrospective cohort study of treatment patterns among patients with metastatic soft tissue sarcoma in the USVictor M Villalobos, Stacey DaCosta Byfield, Sameer R Ghate, et al.
Journal of Medical Economics|June 20, 2013
Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agentsStacey Dacosta Byfield, Elaine Yu, Robert Morlock, et al.
Journal of Neuro-Oncology|May 24, 2013
Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancerSaurabh Ray, Stacey Dacosta-Byfield, Arijit Ganguli, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Trends in Cell Biology|April 2, 2004
Lateral signaling enhances TGF-beta response complexityStacey DaCosta Byfield, Anita B Roberts
Anticancer Research|January 31, 2021
Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort StudyShaum M Kabadi, Stacey Dacosta Byfield, Lisa LE, et al.
Journal of Oncology Practice|September 24, 2015
ReCAP: Treatment Patterns and Cost of Care Associated With Initial Therapy Among Patients Diagnosed With Operable Early-Stage Human Epidermal Growth Factor Receptor 2-Overexpressed Breast Cancer in the United States: A Real-World Retrospective StudyStacey DaCosta Byfield, Philip O Buck, Cori Blauer-Peterson, et al.
Journal of Comparative Effectiveness Research|January 25, 2021
Economic impact of multigene panel testing for hereditary breast and ovarian cancerStacey Dacosta Byfield, Helen Wei, Mary DuCharme, et al.
Archives of Dermatological Research|April 23, 2013
Age distribution of patients with advanced non-melanoma skin cancer in the United StatesStacey Dacosta Byfield, Diana Chen, Yeun Mi Yim, et al.
Molecular Pharmacology|February 24, 2004
SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7Stacey DaCosta Byfield, Christopher Major, Nicholas J Laping, et al.
Leukemia & Lymphoma|July 12, 2013
Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapyB Douglas Smith, Dalia Mahmoud, Stacey Dacosta-Byfield, et al.
Clinical Sarcoma Research|November 21, 2017
A retrospective cohort study of treatment patterns among patients with metastatic soft tissue sarcoma in the USVictor M Villalobos, Stacey DaCosta Byfield, Sameer R Ghate, et al.
Journal of Medical Economics|June 20, 2013
Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agentsStacey Dacosta Byfield, Elaine Yu, Robert Morlock, et al.
Journal of Neuro-Oncology|May 24, 2013
Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancerSaurabh Ray, Stacey Dacosta-Byfield, Arijit Ganguli, et al.
Pageof 3